NEW YORK – Solid Biosciences on Wednesday said it has entered into a collaboration with the Mayo Clinic under which it will have an exclusive license to develop and commercialize six cardiac gene therapy programs using the hospital system's gene therapy platform.
Financial details of the agreement were not disclosed.
As part of the deal, Mayo Clinic will be responsible for R&D efforts for the gene therapies for sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies through investigational new drug (IND)-enabling studies. Solid then will have the option to pursue continued development and commercialization of each licensed program.
The gene therapies will use Charlestown, Massachusetts-based Solid's adeno-associated virus capsids, including one that targets muscles, and the Suppression and Replacement gene therapy platform, which was developed by Mayo Clinic's Windland Smith Rice Sudden Death Genomics Laboratory and to which Solid will have an exclusive license under the terms of the agreement.
Rochester, Minnesota-based Mayo Clinic, which has a financial interest in Solid, said it will use revenue from this collaboration to support patient care, education, and research.